Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: michael meyers who wrote (17272)	3/12/1998 12:33:00 AM
From: Flagrante Delictu	Read Replies (2) \| Respond to of 32384

michael, >> Jill are you listening? << Having a little trouble free-loading information? Life's a beach. I'll bet you made a lot friends here with your veiled threat of siccing the webmistress on us. Before you leave, please inform us what you have done for us.

To: michael meyers who wrote (17272)	3/12/1998 9:25:00 AM
From: bob smith	Read Replies (1) \| Respond to of 32384

>>there were 150 posts today, many of which were worthless.<< I just returned from a weeks trip and found 1200 new posts! How about sifting through this pile of posts for anything worth while reading ?...

To: michael meyers who wrote (17272)	3/12/1998 12:49:00 PM
From: JOEBT1	Respond to of 32384

I'm also fed up with the excessive posts of no value to LGND investors. It's a real waste of time to filter through the posts trying to find something worth reading. I read all of Henry's posts but even he gets in a defensive mode which results in non-useful posts. Others generate some very good posts but get into unnecessary and totally useless bickering. TonyT plays a useful contrarian role that tempers our euphoria about LGND in his posts when he's not defending himself or attacking someone. I have a rule not to post unless I can provide some useful input.My last post about 5 weeks ago pointed out the potential of Targretin/Panretin for breast cancer and synergy when combined with Tamoxifen.Usually I only post after a discussion with Susan Atkins or someone else at LGND. There's been some discussion on bio-tech portfolios. FWIW, here's my views. SEPR has been a great performer but is weakening. CTRX and IMGN are two low priced stocks that can go much higher. HYBN has a lot of potential if can overcome its financial difficulties. XOMA is not moving very fast in its clinical trials but has a lot potential with Neuprex. PCYC and CHRX have good products and management.SCIO is poised for a move up based on Natrecor and Fiblast. All above IMHO. I continue to rank LGND as the best investment-of all the above, IMHO. As far as technical analysis goes I think its a good tool for short term trading in the absence of news. News like the breast cancer results on mice models, small molecule STATS and future results on ovarian. prostate, lung, and head/neck cancers could overwhelm TA projections. The long term investment case for LGND is based on the rich science of LGND's platforms. Pending news on NDA's and start of new trials ( eg, breast cancer and partners trials) will also be a positive market force.